BPS Bioscience, Inc. Press releases
Mar 26, 2015
Adding to an already extensive offering of Immunotherapy products, BPS Bioscience, Inc. (BPS) now provides over 15 exclusive biotin-labeled immunotherapy proteins
Dec 09, 2014
BPS Bioscience, Inc. (“BPS”) announces Ebola virus glycoproteins for drug discovery research use.
Sep 23, 2014
BPS Bioscience, Inc. (“BPS”) announces new kits for screening inhibitors of the histone demethylases FBXL10 & FBXL11 and the histone methyltransferase SETDB1. These unique kits join a large portfolio of kits and proteins for epigenetic research.
Aug 13, 2014
BPS Bioscience, Inc. (BPS) is now offering a KEAP1:Nrf2 Inhibitor Screening Assay Kit
Jun 10, 2014
BPS Bioscience, Inc. (BPS) is now offering its newest cell line: the Hippo Pathway TEAD Reporter – MCF7 Cell Line.
May 29, 2014
BPS Bioscience, Inc. (“BPS”) has developed several new assay kits (BTLA:HVEM, CD28:B7-1, and CTLA4:B7-1) and related proteins to advance immunotherapy research.
Apr 23, 2014
BPS Bioscience, Inc. introduces unique EZH2 mutants and 2 new assay kits for screening EZH2 inhibitors
Oct 31, 2013
Unique Portfolio of Proteins and Assay Kits for PD-1-related Research and Drug Discovery
Oct 14, 2013
BPS Bioscience, Inc. (“BPS”) announces the addition of a panel of 6 protease enzymes for identifying small molecule inhibitors of the Hepatitis C virus (HCV). These unique enzymes are also available for custom screening and profiling services.
Sep 16, 2013
Expanding the Largest Portfolio of Proteins and Assay Kits for Epigenetic Research and Drug Discovery